Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
By Product 9.2.3
"Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial." The Lancet, 2021, 398(10295), 143-155
Genuinely effective obesity drugs, as GLP-1s appear to be, should have a positive impact on the bottom line of US health insurers like Cigna (CI), United Healthcare (UNH), Humana (HUM) and Centene (CNC) in the long term while harming companies paying for these very expensive and likely to be in-demand medications like Insperity (NSP) and Robert Half (RHI)
In individuals with obesity without T2DM, SURMOUNT- 1 evaluated the safety and effectiveness of tirzepatide 5, 10, and 15 mg once weekly in comparison to a placebo when paired with a 500 kcal/day deficit diet and recommendations for 150 min of weekly exercise [118]
Positive and negative impressions were almost equally represented
This represents a statistically significant drop
US$ 28.56
US$ 29.09
US$ 22.07
US$ 21.51
US$ 20.02
US$ 29.08
US$ 21.73
US$ 28.11
US$ 29.63
